| Nope! It won't be, because capitalism. In 2026, patent protections that lapse are going to cause a tidal wave: https://glp1.guide/content/novo-nordisk-patent-protections-l... For context, the previous calculus was: https://glp1.guide/content/patent-expirations-for-glp1-recep... (~2033 for the US) Theoretically, the tidal wave of generic Semaglutide wouldn't hit the US or EU due to patent protections there... But see the aforementioned note about capitalism. Note that there is already generic Liraglutide as well: https://glp1.guide/content/another-generic-liraglutide-launc... Tirzepatide (Mounjaro/Zepbound) > Semaglutide (Ozempic/Wegovy/Rybelsus) > Liraglutide But having any of these available is a step change. > (...who might be the target market - being overweight might be a disease of affluence) This might be true on the margin but is mostly untrue these days. The lack of access to healthy unprocessed food and the free time to exercise are becoming increasingly problems for those who are NOT wealthy. |